Gallinger, S.

Dr. Steven Gallinger
Division of General Surgery
Toronto General Hospital
200 Elizabeth Street
Toronto, ON
M5G 2C4

Tel: 416 586-8550
Fax: 416 586-8392

Dr. Steven Gallinger


Medical School:
University of Toronto

Fellowship Training:
Toronto General Hospital

Dr. Steven Gallinger is a graduate of the University of Toronto General Surgery Training program, and completed the HPB/transplant fellowship at The Toronto General Hospital in 1988. During his residency he completed his MSc under the supervision of Steve Strasberg as an SSTP resident in the area of cholesterol gallstone pathogenesis. Following his fellowship training, he trained as a PDF in the field of molecular immunology in the laboratory of John Roder at the Lunenfeld. From 1990 to 2008, he was a member of the Division of General Surgery at Mount Sinai Hospital where he also set up his research program at the Lunenfeld in the field of GI cancer genetics. He moved his clinical practice to TGH in 2008 to foster the growth of the HPB program at UHN where he works with a group of 10 HPB/transplant surgeons.

His laboratory has taken a multipronged approach to understand inherited predisposition to colorectal and pancreas cancer. First, large population based registries have been developed using incident cases in Ontario identified by the Ontario Cancer Registry at Cancer Care Ontario from 1997 to the present (the Ontario Familial Colorectal Cancer Registry and the Ontario Pancreas Cancer Study). Family history and epidemiologic questionnaires have been administered to these subjects and biospecimens (including blood and tumors) banked at the Biospecimen Repository at Mount Sinai Hospital. These registries have been supplemented by clinic-based cases enrolled through the HPB program at UHN and the Zane Cohen Digestive Diseases Centre at Mount Sinai Hospital where he is co-Director. Second, knockout mouse models have been used to characterise both germline and somatic mutational events during colorectal tumorigenesis, and to study chemopreventive agents including COX-2 inhibitors. A third and recent set of studies includes characterising germline genomic copy number variation as a novel mechanism underlying human phenotypic variation, including susceptibility to cancer.

Dr. Gallinger is also Head of the Hepatobiliary/pancreatic surgical oncology program at Mount Sinai Hospital and UHN, and Chair of the CCO HPB surgical oncology working group which is implementing volume/outcome based principles to standardise guidelines for HPB surgical oncology care in Ontario.